Datapoint: Roche Scores Expanded SMA Nod for Evrysdi

The FDA this week approved Roche’s at-home spinal muscular atrophy (SMA) therapy Evrysdi in children under two months old. The treatment was first approved for SMA in adults and older children in August 2020. It currently holds covered or better status for 81% of all insured lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 6/1/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 23

Datapoint: Skyrizi Scores Crohn’s Disease Nod

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 22

Datapoint: Merck-Seagen Deal Could Be in the Works

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 21

Datapoint: Centene Settles New Mexico Medicaid Dispute

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today